Cardinal Health, US14149Y1082

Charles River Labs Stock - Background and strategy snapshot

Published on 06/17/2026 at 19:26 | Editorial responsibility: Rafael MĂĽller, Editor-in-Chief AD HOC NEWS

Charles River Laboratories stock attracts attention as investors reassess the contract research specialist’s business model, growth drivers and regulatory backdrop. A look at how the group earns its money and where the shares trade today.

Cardinal Health, US14149Y1082, Illustration mit AI erstellt.
Cardinal Health, US14149Y1082, Illustration mit AI erstellt.

Edited by ad hoc news Operations & Strategy Desk. Verified prior to publication on 06/17/2026, 19:25 UTC. Details in the imprint.

Charles River Laboratories (US14149Y1082) is a US-based contract research organization focused on early-stage drug development services. With no fresh corporate filings or major analyst actions today, the focus shifts to its operating model and strategic position in the life sciences outsourcing market.

Go deeper

Background and price data on Charles River Laboratories stock

All news, background and regulatory filings on Charles River Laboratories stock are bundled in the ad hoc news dossier and on the company’s Investor Relations site.

How Charles River earns its fees

Charles River Laboratories International Inc. describes itself as a full-service, early-stage contract research organization supporting biotechnology and pharmaceutical clients across the drug discovery and preclinical pipeline.

The group’s main activities include safety assessment, discovery services, and manufacturing support for cell and gene therapies, biologics and small molecules.

Operational footprint and strategy

The company operates a global network of laboratories and facilities, with a significant presence in North America and Europe, and additional sites in Asia.

Management emphasizes integrated service offerings, aiming to reduce timelines and complexity for clients that increasingly outsource early R&D tasks to specialized providers.

What the company sells

At the core of Charles River’s activity is preclinical safety assessment, where it conducts toxicology and related studies on candidate drugs before they enter clinical trials, alongside discovery research services, biologics testing, and support for advanced therapies.

Where the stock trades today

Charles River Laboratories stock is listed on the New York Stock Exchange under the ticker CRL; current share price data and market capitalization are available on major market data portals and the NYSE quote page.

Key facts on Charles River Laboratories stock

  • Company: Charles River Laboratories International Inc.
  • ISIN: US14149Y1082
  • Ticker: CRL
  • Venue: NYSE
  • Sector / Industry: Health Care - Life Sciences Tools & Services

More on Charles River Laboratories stock on social media

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.

Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.

en | US14149Y1082 | CARDINAL HEALTH | boerse | 69565339 | bgmi